Human Immunodeficiency Virus Infection Clinical Trial
— QD-KapitalOfficial title:
Treatment Perception of QD Dosed Kaletra (Tablets) Based Treatment in HIV Infected Patients. Observational Cross-Sectional Study (QD-KAPITAL)
Verified date | April 2013 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Spanish Agency of Medicines |
Study type | Observational |
Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease
inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).
Since once-a-day dosing is actually a driver for human immunodeficiency virus (HIV)-infected
patients to request a specific antiretroviral, the aim of this study is to assess both
patient's perception of and adherence to Kaletra once-a-day, as well as with which factors
they are related.
Status | Completed |
Enrollment | 97 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: 1. Men or women aged 18 years or older, HIV-infected. 2. Patients who were under LPV/r Highly Active Anti-Retroviral Therapy (HAART) for 3 to 24 months before study visit: Cohort 1: patients on LPV/r QD since they started the LPV/r regimen and who were naïve to protease inhibitor (PI) therapy.* Cohort 2: patients who previously started on LPV/r BID (maximum of 24 months before study) and switched to LPV/r QD (at least 3 months before the study visit).* 3. Patients who were able to complete questionnaires by themselves. 4. Patients who signed/dated informed consent to participate in the study. - NOTE: Patients who were taking LPV/r QD should have had no more than 3 protease inhibitor mutations by the time the treatment with this LPV/r dosing was initiated. Exclusion criteria: 1. Patients who were on LPV/r monotherapy or bi-therapy or on BID dosing at time of study visit. 2. Patients who were using another LPV/r formulation different from 200/50 LPV/r mg tablets. 3. Patients who were participating in any other clinical trial or postmarketing observational study (PMOS). 4. Patients who were unable to read and/or write. 5. Patients who were under treatment interruption. Patients who have stopped LPV-therapy for more than 3 months in the 12 months preceding study visit. |
Observational Model: Cohort, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Spain | Site Ref # / Investigator 52274 | A Coruna | |
Spain | Site Ref # / Investigator 52363 | Barakaldo | |
Spain | Site Ref # / Investigator 52270 | Barcelona | |
Spain | Site Ref # / Investigator 52271 | Barcelona | |
Spain | Site Ref # / Investigator 52362 | Cartagena | |
Spain | Site Ref # / Investigator 53650 | Castellon de la Plana | |
Spain | Site Ref # / Investigator 52273 | Ferrol (A Coruna) | |
Spain | Site Ref # / Investigator 52264 | Granada | |
Spain | Site Ref # / Investigator 52267 | Hospitalet de Llobregat | |
Spain | Site Ref # / Investigator 52262 | Jaen | |
Spain | Site Ref # / Investigator 52263 | Jerez de la Frontera (Cadiz) | |
Spain | Site Ref # / Investigator 52275 | Madrid | |
Spain | Site Ref # / Investigator 52302 | Madrid | |
Spain | Site Ref # / Investigator 52343 | Madrid | |
Spain | Site Ref # / Investigator 52344 | Madrid | |
Spain | Site Ref # / Investigator 52345 | Madrid | |
Spain | Site Ref # / Investigator 53648 | Murcia | |
Spain | Site Ref # / Investigator 52268 | Reus (Tarragona) | |
Spain | Site Ref # / Investigator 52272 | Valencia | |
Spain | Site Ref # / Investigator 52266 | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) | Triaca Magna, SA |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Individual Item Scores for the Overall Study Population | Participant treatment satisfaction was measured using the HIVTSQ, which consists of 10 items (1-Satisfaction, 2-HIV Control, 3-Adverse Effects, 4-Level of Demand, 5-Convenience, 6-Flexibility, 7-Knowledge, 8-Life Habits, 9-Recommendability, and 10-Willingness to Continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). Each single item was considered for the evaluation of the primary outcome. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Primary | Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ)Dimension (Overall Satisfaction, General/Clinical Satisfaction, Lifestyle) Scores for the Overall Study Population | The HIVTSQ consists of 10 items (1-Satisfaction, 2-HIV Control, 3-Adverse Effects, 4-Level of Demand, 5-Convenience, 6-Flexibility, 7-Knowledge, 8-Life Habits, 9-Recommendability, and 10-Willingness to Continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The items are aggregated to 3 different dimensions: the Overall Satisfaction dimension, with a maximum score of 54 (items 1, 2, 3, 5, 6, 7, 8, 9 and 10); General/Clinical Satisfaction dimension, with a maximum score of 30 (items 1, 2, 3, 9 and 10); Lifestyle dimension, with a maximum score of 24 (items 5, 6, 7 and 8). Each dimension was considered for the evaluation of the primary outcome. For each participant, each dimension score was calculated as a sum of the individual item scores. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Individual Item Scores Comparison Between Cohorts | The HIVTSQ consists of 10 items (1-Satisfaction, 2-HIV Control, 3-Adverse Effects, 4-Level of Demand, 5-Convenience, 6-Flexibility, 7-Knowledge, 8-Life Habits, 9-Recommendability, and 10-Willingness to Continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The mean score per item was compared between cohorts. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Dimension (Overall Satisfaction, General/Clinical Satisfaction, Lifestyle) Scores Comparison Between Cohorts | The HIVTSQ consists of 10 items (1-Satisfaction, 2-HIV Control, 3-Adverse Effects, 4-Level of Demand, 5-Convenience, 6-Flexibility, 7-Knowledge, 8-Life Habits, 9-Recommendability, and 10-Willingness to Continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The items are aggregated to 3 different dimensions: the Overall Satisfaction dimension, with a maximum score of 54 (items 1, 2, 3, 5, 6, 7, 8, 9 and 10); General/Clinical Satisfaction dimension, with a maximum score of 30 (items 1, 2, 3, 9 and 10); Lifestyle dimension, with a maximum score of 24 (items 5, 6, 7 and 8). The mean score per dimension was compared between cohorts. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Number of Days Without Medication, Per Simplified Medication Adherence Questionnaire (SMAQ) | Number of days without medication was assessed by 1 of the 6 items on the patient questionnaire Simplified Medication Adherence Questionnaire (SMAQ): How many full days have you missed your medication since your last visit? (Please see Outcome Measure 6 for details regarding the remaining 5 items on the SMAQ.) | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Adherence Classification of Participants Per Simplified Medication Adherence Questionnaire (SMAQ) | Participants' adherence was classified according to answers for 5 of 6 items on the participant questionnaire Simplified Medication Adherence Questionnaire (SMAQ): 4 yes/no questions: Do you ever forget to take your medicines? Do you take your medicines at the instructed time? If you ever feel ill, do you stop taking the medication? Have you ever missed your medication during weekends?; plus the following: In the past week, how many times have you missed your medication? (0, 1-2, 3-5, 6-10, >10). (Please see Outcome Measure 5 for details regarding the 6th item on the SMAQ.) Perfect adherence = no dose was forgotten, medication was not skipped for any reason, and the schedule was not modified; adequate adherence = no dose was forgotten, but at least one dose was not taken at the indicated time; poor adherence = one or more doses were not taken. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Reasons for Starting or Switching to a Lopinavir/Ritonavir Once Daily (LPV/r QD)Regimen | Participants' cumulative reasons for starting or switching to a LPV/r QD regimen were tabulated via the following yes/no questions entered on the case report form by the physician: simplification (simp) as reason to change to LPV/r QD; preference (pref) of patient as reason to change to LPV/r QD; adjustment to other antiretrovirals (adjust to ARV) as reason to change to LPV/r QD; adherence as reason to change to LPV/r QD; patient's lifestyle as reason to change to LPV/r QD; tolerability as reason to change to LPV/r QD. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Percentage of Participants With a Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Overall Satisfaction Dimension Mean Score Value of =5 and <5 | The HIVTSQ consists of 10 items (1-Satisfaction, 2-HIV Control, 3-Adverse Effects, 4-Level of Demand, 5-Convenience, 6-Flexibility, 7-Knowledge, 8-Life Habits, 9-Recommendability, and 10-Willingness to Continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The items are aggregated to 3 different dimensions. The Overall Satisfaction dimension has a maximum score of 54 (items 1, 2, 3, 5, 6, 7, 8, 9 and 10). The mean of the individual item scores were dichotomized as 'mean score <5 (lower participant perception of LPV/r QD)' and 'mean score =5 (high or very high participant perception of LPV/r QD).' The dependent variable of a mean score <5 was correlated with the independent variables of viral load and time on treatment (see Outcome Measures 9 and 10), to determine the factors associated with a participant's lower perception of QD LPV/r treatment. | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Viral Load (VL) Change After at Least 12 Weeks of Treatment With the Lopinavir/Ritonavir (LPV/r) | Viral load change was categorized as either 'detectable to undetectable,' 'undetectable to undetectable,' or 'current detectable' (includes participants whose viral load changed from undetectable to detectable and those whose viral load was detectable throughout). This independent variable was correlated with the percentage of participants with the dependent variable of a Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Overall Satisfaction dimension mean score value of <5 (see Outcome Measure 8), to determine the factors associated with a participant's lower perception of QD LPV/r treatment (see statistical analyses for odds ratio). | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Mean Number of Days on LPV/r QD | This independent variable was correlated with the percentage of participants with the dependent variable of an HIVTSQ Overall Satisfaction dimension mean score value of <5 (see Outcome Measure 8), to determine the factors associated with a participant's lower perception of QD LPV/r treatment (see statistical analysis for odds ratio). | At the single study visit, performed after at least 12 weeks of treatment with Kaletra QD | No |
Secondary | Comparison of Mean Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Dimension Scores From QD-KAPITAL and KAPITAL2 Studies | Participants' perceptions of the QD and BID LPV/r regimens using data from the overall study population of QD-KAPITAL and from Cohort 2 of a 2007-2008 study, respectively (KAPITAL2, Casado et al. See Detailed Description for full reference). The KAPITAL2 cohort was comprised of HIV-infected participants treated with LPV/r BID from =3 months to <2 years for at least 1 month before inclusion in the study. Data for the overall study population of QD-KAPITAL are provided here, but a comparison to Cohort 2 from the KAPITAL2 study is not presented. | at the single study visit, performed after at least 12 weeks of treatment with Kaletra | No |
Secondary | Percentage of Participants With Missing Doses During "the Past 4 Days" and "the Last Weekend" in KAPITAL-2 and QD-KAPITAL Studies | Adherence to LPV/r QD therapy (overall study population of QD-KAPITAL) compared with that of LPV/r BID therapy using data of Cohort 2 from a 2007-2008 study, respectively (KAPITAL2, Casado et al. See Detailed Description for full reference). The KAPITAL2 cohort was comprised of HIV-infected participants treated with LPV/r BID from =3 months to <2 years for at least 1 month before inclusion in the study. (A full comparison of the adherence between the QD-KAPITAL study and the KAPITAL2 study could not be made due to formal differences in the applied adherence questionnaires; therefore, the above in-common specified item was compared.) Data for the overall study population of QD-KAPITAL are provided here, but a comparison to Cohort 2 from the KAPITAL2 study is not presented. | at the single study visit, performed after at least 12 weeks of treatment with Kaletra | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05981807 -
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
|
||
Completed |
NCT01490359 -
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
|
N/A | |
Completed |
NCT03143205 -
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
|
N/A | |
Completed |
NCT02738138 -
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
|
Phase 3 | |
Completed |
NCT01791465 -
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
|
Phase 4 | |
Completed |
NCT01869634 -
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
|
Phase 4 | |
Completed |
NCT01662336 -
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
|
N/A | |
Completed |
NCT01328158 -
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
|
N/A | |
Completed |
NCT00711009 -
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
|
Phase 3 | |
Completed |
NCT02817451 -
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
|
Phase 3 | |
Completed |
NCT02214173 -
The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV
|
N/A | |
Completed |
NCT03284645 -
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
|
||
Terminated |
NCT01737359 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
|
Phase 2 | |
Active, not recruiting |
NCT05141422 -
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01939197 -
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
|
Phase 2/Phase 3 | |
Completed |
NCT01447680 -
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
|
N/A | |
Not yet recruiting |
NCT05769413 -
Awareness of Osteoporosis in HIV Patients
|
||
Withdrawn |
NCT01738555 -
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
|
Phase 2 |